NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s stock price was down 8.4% during mid-day trading on Monday . The company traded as low as $0.90 and last traded at $0.87, approximately 6,532 shares were traded during trading. A decline of 99% from the average daily volume of 1,226,033 shares. The stock had previously closed at $0.95.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.12). The firm had revenue of $1.49 million during the quarter.
In other news, major shareholder Pharma (Hong Kong) Co Pioneer sold 24,326 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $4.04, for a total transaction of $98,277.04. Following the completion of the sale, the insider now owns 5,188,421 shares in the company, valued at approximately $20,961,220.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mijia Wu sold 63,492 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $2.53, for a total value of $160,634.76. The disclosure for this sale can be found here.
NovaBay Pharmaceuticals Company Profile (NYSEAMERICAN:NBY)
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Recommended Story: How to calculate the annual rate of depreciation
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.